The Intensive Medicines Monitoring Programme undertakes prospective, observational, cohort studies on selected new medicines. These are aimed at measuring the incidence of adverse reactions, their characterisation, the early identification of previously unrecognised reactions and the construction of a risk profile for each medicine. The results are reported to the Ministry of Health and the health professions. It has a considerable international reputation. Medicines on the Intensive Medicines Monitoring Programme (IMMP) varenicline (Champix) Event reporting form available here

NEWS Reporting Form for Immunisations Influenza Vaccine Reporting

CARM | IMMP | Reporting | Publications | Staff | Contact | Links